

To: State Pharmaceutical Assistance Programs, Entities Providing Other Prescription Drug Coverage, Authorized Prescribers, Network Pharmacies, and Pharmacists

From: Prime Therapeutics LLC

Subject: June 2025 Notification of Medicare Part D Negative Formulary Change(s)

Prime Therapeutics LLC (Prime) manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. Prime supports several Medicare Part D Plan Sponsors (Part D Sponsors) and serves over 1 million Medicare beneficiaries. During the year, the Centers for Medicare & Medicaid Services (CMS) may approve changes including the removal of drugs or the addition of restrictions or limits to certain drugs, to the list of Medicare Part D covered drugs. When CMS approves a change, Prime provides at least 30 days notice to both the Part D Sponsors' impacted members and other individuals and organizations that may work with these members, before the negative formulary change(s) take effect. When the change is because the Food and Drug Administration deems a Part D drug to be unsafe, the manufacturer removes the drug from market, or a brand drug is replaced with its generic or is tier raised, Prime will provide retrospective notice as soon as possible. In accordance with Medicare Part D requirements and CMS' approval, Prime is providing notification of the following Medicare Part D negative formulary change(s):

Drug	Type of Change	Reason for Change	Effective Date of Change	Formulary/Formularies Impacted
BRILINTA - ticagrelor tab, 60 mg	Will be removed from drug list	Generic now available	06/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE) MAPD Formularies (Classic, DSB, Value) Client Specific Formularies (Alignment, Asuris, Braven, Capital Blue Cross, HCSC, Horizon, Rhode Island, Regence)
BRILINTA - ticagrelor tab, 90 mg	Will be removed from drug list	Generic now available	06/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE) MAPD Formularies (Classic, DSB, Value) Client Specific Formularies (Alignment, Asuris, Braven, Capital



Drug	Type of Change	Reason for Change	Effective Date of Change	Formulary/Formularies Impacted
				Blue Cross, HCSC, Horizon, Rhode Island, Regence)
APTIOM - eslicarbazepine acetate tab, 200 mg	Will be removed from drug list	Generic now available	06/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE) MAPD Formularies (Classic, DSB, Value) Client Specific Formularies (Alignment, Asuris, Braven, Capital Blue Cross, HCSC, Horizon, Rhode Island, Regence)
APTIOM - eslicarbazepine acetate tab, 400 mg	Will be removed from drug list	Generic now available	06/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE) MAPD Formularies (Classic, DSB, Value) Client Specific Formularies (Alignment, Asuris, Braven, Capital Blue Cross, HCSC, Horizon, Rhode Island, Regence)
APTIOM - eslicarbazepine acetate tab, 600 mg	Will be removed from drug list	Generic now available	06/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE) MAPD Formularies (Classic, DSB, Value) Client Specific Formularies (Alignment, Asuris, Braven, Capital Blue Cross, HCSC, Horizon, Rhode Island, Regence)
APTIOM - eslicarbazepine acetate tab, 800 mg	Will be removed from drug list	Generic now available	06/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE) MAPD Formularies (Classic, DSB, Value) Client Specific Formularies (Alignment, Asuris, Braven, Capital Blue Cross, HCSC, Horizon, Rhode Island, Regence)



The Part D Sponsors' members who are impacted by the change(s) will receive notification on their monthly Explanation of Benefits (EoB). Since you may interact with the Part D Sponsors' members, Prime is providing you this notice prior to the date the change becomes effective so that you may take any appropriate action as you work with the Part D Sponsors' members, which may include considering alternative drugs that are covered by the plan or asking the plan for an exception.

For more information about how the change(s) may affect cost-sharing, such as copayments or coinsurance, or for more information about asking the plan for an exception, please visit <u>MyPrime.com</u>. (Note: There is no access to Regence or Asuris on MyPrime.com. Please visit Regence.com or Asuris.com for additional information on those health plans).

Prior Negative Formulary Changes in 2025

Drug	Type of Change	Reason for Change	Effective Date of Change	Formulary/Formularies Impacted
AMZEEQ - minocycline hcl micronized foam, 4%	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Complete, Elite)
BENZNIDAZOLE tab, 12.5 mg, 100 mg	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE) MAPD Formularies (Classic, Complete, DSB, Elite, Premier, Value) Client Specific Formularies (Alignment, Asuris, Braven, Capital Blue Cross, HCSC, Horizon, Rhode Island, Regence)
CETRAXAL - ciprofloxacin hcl otic soln, 0.2%	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Complete, Elite)
CIPROFLOXACIN/FLUOCINOLONE ACETONIDE PF otic soln, 0.3- 0.025%	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Complete, Elite)
CONJUPRI - levamlodipine maleate tab, 2.5 mg, 5 mg	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Complete, Elite)
ESTROGEL - estradiol gel pump, 0.06% (0.75 mg/1.25 gm metered-dose)	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Complete, Elite)



			Effective Date	THESABELTICS
Drug	Type of Change	Reason for Change	of Change	Formulary/Formularies Impacted
EXELDERM - sulconazole nitrate	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
cream, 1%		Medicare Part D		Elite)
EXELDERM - sulconazole nitrate	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
solution, 1%		Medicare Part D		Elite)
LEVAMLODIPINE maleate tab,	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
2.5 mg, 5 mg		Medicare Part D		Elite)
NALFON - fenoprofen calcium	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
cap, 400 mg		Medicare Part D		Elite)
NUVESSA - metronidazole	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
vaginal gel, 1.3%		Medicare Part D		Elite)
ORALAIR - grass mixed pollen ext	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete, Elite,
sl tab, 300 ir (index of reactivity)		Medicare Part D		Premier)
				Client Specific Formularies
				(Alignment)
OTOVEL - ciprofloxacin-	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
fluocinolone aceton (pf) otic		Medicare Part D		Elite)
soln, 0.3-0.025%				
QBREXZA - glycopyrronium	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
tosylate pad, 2.4%		Medicare Part D		Elite)
SLYND - drospirenone tab, 4 mg	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
		Medicare Part D		Elite)
SPRYCEL – dasatinib tab, 20 mg,	Will be removed from drug list	Generic now available	01/01/2025	Center of Excellence Formularies
50 mg, 70 mg, 80 mg, 100 mg,				(Basic, Enhanced, HCE)
140 mg				MAPD Formularies (Classic, DSB,
				Value)
				Client Specific Formularies
				(Alignment, Asuris, Braven, Capital
				Blue Cross, HCSC, Horizon, Rhode
				Island, Regence)
SYNAGIS - palivuzumab im soln,	Will be removed from drug list	No longer covered by	01/01/2025	Client Specific Formularies
50 mg/0.5ml, 100 mg/1ml		Medicare Part D		(Alignment)
SYNDROS - dronabinol soln, 5	Will be removed from drug list	No longer covered by	01/01/2025	MAPD Formularies (Complete,
mg/ml		Medicare Part D		Elite)



				THERAPPUTICS
Drug	Type of Change	Reason for Change	Effective Date of Change	Formulary/Formularies Impacted
TYBLUME - levonorgestrel & ethinyl estradiol chew tab, 0.1 mg-20 mcg	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Classic, Complete, DSB, Elite, Premier, Value) Client Specific Formularies (Asuris, Braven, HCSC, Horizon, Rhode Island, Regence)
XENLETA - lefamulin acetate tab, 600 mg	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Complete, Elite)
XPHOZAH – tenapanor hcl tab, 20 mg, 30 mg	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Complete, Elite)
XURIDEN - uridine triacetate oral granules packet, 2 gm	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Complete, Elite)
ZOKINVY - lonafarnib cap, 50 mg, 75 mg	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE) MAPD Formularies (Classic, Complete, DSB, Elite, Premier, Value) Client Specific Formularies (Alignment, Asuris, Braven, Capital Blue Cross, HCSC, Horizon, Rhode Island, Regence)
ZONTIVITY - vorapaxar sulfate tab, 2.08 mg	Will be removed from drug list	No longer covered by Medicare Part D	01/01/2025	MAPD Formularies (Classic, Complete, DSB, Elite, Premier) Client Specific Formularies (Alignment, HCSC)
MESNEX - mesna tab, 400 mg	Will be removed from drug list	Generic now available	02/01/2025	Client Specific Formularies (Alignment)
NEXIUM - esomeprazole magnesium for delayed release susp pack, 2.5 mg	Will be removed from drug list	Generic now available	02/01/2025	Client Specific Formularies (Alignment)
NEXIUM - esomeprazole magnesium for delayed release susp packet, 5 mg	Will be removed from drug list	Generic now available	02/01/2025	Client Specific Formularies (Alignment)
PREHEVBRIO - hepatitis b vaccine 3-antigen (recombinant) susp, 10 mcg/ml	Will be removed from drug list	No longer covered by Medicare Part D	05/01/2025	Center of Excellence Formularies (Basic, Enhanced, HCE)



Drug	Type of Change	Reason for Change	Effective Date of Change	Formulary/Formularies Impacted
				MAPD Formularies (Classic,
				Complete, DSB, Elite, Premier,
				Value)
				Client Specific Formularies
				(Alignment, Asuris, Braven, Capital
				Blue Cross, HCSC, Horizon, Rhode
				Island, Regence)